REGENXBIO Inc. (RGNX)
| Market Cap | 524.47M +12.9% |
| Revenue (ttm) | 174.48M +12.0% |
| Net Income | -196.43M |
| EPS | -3.77 |
| Shares Out | 66.01M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,427,110 |
| Open | 8.69 |
| Previous Close | 8.69 |
| Day's Range | 7.78 - 8.75 |
| 52-Week Range | 5.46 - 16.19 |
| Beta | 0.93 |
| Analysts | Buy |
| Price Target | 23.73 (+198.68%) |
| Earnings Date | Aug 6, 2026 |
About RGNX
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-12... [Read more]
Financial Performance
In 2025, REGENXBIO's revenue was $170.44 million, an increase of 104.54% compared to the previous year's $83.33 million. Losses were -$193.88 million, -14.63% less than in 2024.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for RGNX stock is "Buy." The 12-month stock price target is $23.73, which is an increase of 198.68% from the latest price.
News
REGENXBIO Transcript: 2026 Global Healthcare Conference
The company is advancing late-stage gene therapy programs in DMD and ophthalmology, with RGX-202 showing strong efficacy and safety data and a BLA submission planned for early next year. Large pivotal trials in wet AMD are nearing top-line data, and financial resources are expected to last into late 2027.
REGENXBIO to Participate in Upcoming Investor Conferences
ROCKVILLE, Md., Sept. 8, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences: Baird 2026 Global Healthcare Conference Fireside ...
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of REGENXBIO Inc. (RGNX)
SAN DIEGO--(BUSINESS WIRE)---- $RGNX #BiotechInvesting--Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of REGENXBIO Inc. (NASDAQ: RGNX) against cer...
Regenxbio price target lowered to $21 from $23 at H.C. Wainwright
H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Regenxbio (RGNX) to $21 from $23 and keeps a Buy rating on the shares after the FDA had placed…
REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli
ROCKVILLE, Md., Aug. 25, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the appointment of Greg Ciongoli to its Board of Directors, effective August 25, 2026.
Regenxbio price target lowered to $29 from $32 at Baird
Baird analyst Brian Skorney lowered the firm’s price target on Regenxbio (RGNX) to $29 from $32 and keeps an Outperform rating on the shares. The firm updated its model following…
Regenxbio price target lowered to $32 from $45 at Clear Street
Clear Street analyst Bill Maughan lowered the firm’s price target on Regenxbio (RGNX) to $32 from $45 and keeps a Buy rating on the shares. The firm cites the clinical…
RGNX Investor Notice: Johnson Fistel Investigates REGENXBIO Inc. Following Clinical Hold
SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating REGENXBIO Inc. (NASDAQ: RGNX) on behalf of investors who suffered losses and whether those losses may be recoverable ...
BofA says Regenxbio’s MPS setback ‘disappointing,’ larger catalysts intact
BofA says that the clinical hold on Regenxbio’s (RGNX) RGX-121 — after asymptomatic spine MRI findings in five MPS II participants — is “disappointing” and reverses July’s progress. While Regenxbio…
Morning Movers: Regenxbio sinks following clinical hold on RGX-121
Stock futures are pointing to a weaker open as the market comes off a losing week for all three major indexes, with technology stocks particularly pressured by the recent rise…
Regenxbio Stock Sinks 22% Following Surprise Finding in Gene Therapy Trial
Regenxbio reports the discovery of nodules and masses on the spines of patients enrolled in a trial for RGX-121, the company's investigational therapy for Hunter syndome.
Regenxbio to resume trading at 7:25 am ET
Regenxbio (RGNX) is scheduled to resume quoting at 7:20 am ET and to resume trading at 7:25 am ET, according to Nasdaq. Shares were halted, pending news, ahead of the…
FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome
Regenxbio said on Monday the U.S. Food and Drug Administration has placed its experimental gene therapy for Hunter syndrome on clinical hold after spinal scans found abnormalities in five study p...
Regenxbio reports FDA placed clinical hold on RGX-121
Regenxbio (RGNX) provided an update on its investigational gene therapy, RGX-121, for the treatment of Mucopolysaccharidosis type II, also known as Hunter Syndrome. The U.S. Food and Drug Administrati...
REGENXBIO Announces Regulatory Update on RGX-121 for MPS II
ROCKVILLE, Md., Aug. 24, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today provided an update on its investigational gene therapy, RGX-121 (clemidsogene lanparvovec), for the treatment of Mucop...
Regenxbio price target lowered to $23 from $26 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Regenxbio (RGNX) to $23 from $26 and keeps a Buy rating on the shares post the Q2 report. The firm cites the…
Regenxbio price target raised to $18 from $16 at Morgan Stanley
Morgan Stanley analyst Judah Frommer raised the firm’s price target on Regenxbio (RGNX) to $18 from $16 and keeps an Overweight rating on the shares.
Regenxbio downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Eliana Merle downgraded Regenxbio (RGNX) to Equal Weight from Overweight with an unchanged price target of $12. The firm sees potential upside for the company’s wholly-owned RGX-202 f...
REGENXBIO Earnings Call Transcript: Q2 2026
Key milestones achieved in late-stage gene therapy programs, including full enrollment in pivotal studies and FDA alignment for accelerated approval. Financial position strengthened with over $310 million pro forma cash, supporting a runway into Q4 2027 and multiple upcoming regulatory and commercial milestones.
REGENXBIO Earnings release: Q2 2026
REGENXBIO released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
REGENXBIO Quarterly report: Q2 2026
REGENXBIO has published its Q2 2026 quarterly earnings report on August 6, 2026.
Regenxbio reports Q2 EPS 43c vs. ($1.38) last year
Reports Q2 revenue $108M, consensus $96.46M. “Our second quarter was defined by strong clinical execution across our pipeline: the Phase III AFFINITY DUCHENNE trial met its primary endpoint, we dosed…
REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights
RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q3 2026 initiation, with potential accelerated approval in 2H 2027 Long-term surabgene lomparvovec (sura-vec, ABBV-RGX-314) data hig...
REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights
ROCKVILLE, Md., Aug. 3, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, August 6, at 8:00 a.m.
Regenxbio presents long-term data for surabgene lomparvovec
Regenxbio (RGNX) announced positive data from long-term follow-up studies of investigational surabgene lomparvovec in wet AMD using subretinal delivery and diabetic retinopathy, DR, using suprachoroid...